A Phase II, Multicenter, Single-Arm Study OF MPDL3280A in Patients with PD-L1−Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Diseases and Conditions Researched


What is the purpose of this trial?

This multicenter, single-arm study will evaluate the efficacy and safety of MPDL 3280A in patients with PD-L1-positive locally advanced or metastatic non-small c ell lung cancer (NSCLC). Patients will receive an intravenous dose of 1200 mg MP DL3280A on Day 1 of 21-day cycles for a maximum of 16 cycles.

Participation Guidelines

Age: 18 Years and older
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: Hoffman-La Roche
Last Updated:
Study HIC#: 1312013120